Results 61 to 70 of about 2,223,665 (257)
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
, 2017 Previously, we demonstrated that the multiple kinase inhibitor sorafenib mediates the repression of phospho-STAT3 in hepatocellular carcinoma cells.
陳昆鋒;陳培哲 +1 more
core +1 more source
Mechanisms of Reversible Sorafenib Resistance in Hepatocellular Carcinoma [PDF]
, 2016 Conventional wisdom in oncology is that drug resistance is a stable and heritable phenotype due largely to cancer cell acquisition of genetic alterations.
Kuczynski, Elizabeth Anne
core +2 more sources
, 2011 BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti- angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC).
HSU, CHIH-HUNG;SHEN, YING-CHUN;LIN, ZONG-ZHE;CHEN, PEI-JER;SHAO, YU-YUN;DING, YEA-HUI;HSU, CHIUN;CHENG, ANN-LII +1 more
core +1 more source
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. [PDF]
, 2017 PURPOSE: Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the treatment, therefore, we tried to unravel the underlying mechanism in the ...
송재진, 최혜진
core +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma [PDF]
, 2019 Objective: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown.
Moeini, Agrin +16 more
core +1 more source
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Molecular Oncology, EarlyView.Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source
Stem Cell Research & Therapy, 2023 Background Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug.
Sining Zhou +10 more
doaj +1 more source
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
, 2018 Hepatocellular carcinoma is one of most common solid cancers worldwide. Sorafenib is indicated as a treatment for advanced hepatocellular carcinoma (HCC).
Yao Yao +8 more
core +1 more source
Molecular Oncology, EarlyView.This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source